Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kymera Therapeutics (KYMR) Treasury Shares: 2019-2024

Historic Treasury Shares for Kymera Therapeutics (KYMR) over the last 6 years, with Dec 2024 value amounting to $749,604.

  • Kymera Therapeutics' Treasury Shares rose 74.39% to $1.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.4 million, marking a year-over-year increase of 74.39%. This contributed to the annual value of $749,604 for FY2024, which is 26.38% up from last year.
  • As of FY2024, Kymera Therapeutics' Treasury Shares stood at $749,604, which was up 26.38% from $593,140 recorded in FY2023.
  • Kymera Therapeutics' Treasury Shares' 5-year high stood at $749,604 during FY2024, with a 5-year trough of $37,745 in FY2021.
  • For the 3-year period, Kymera Therapeutics' Treasury Shares averaged around $541,529, with its median value being $593,140 (2023).
  • In the last 5 years, Kymera Therapeutics' Treasury Shares crashed by 65.72% in 2021 and then soared by 646.70% in 2022.
  • Yearly analysis of 5 years shows Kymera Therapeutics' Treasury Shares stood at $110,104 in 2020, then plummeted by 65.72% to $37,745 in 2021, then spiked by 646.70% to $281,843 in 2022, then skyrocketed by 110.45% to $593,140 in 2023, then grew by 26.38% to $749,604 in 2024.